Petratherm backed by seasoned resources execs
Mineral sands heavyweight Rob Sennitt has joined Petratherm’s board as an executive director.
Stockhead
ASX struggles into green to post 0.16pc gain
The ASX has managed to claw its way into a 0.16pc gain after an uncertain day of trading, while Woodside Energy’s AGM was overshadowed by a shareholder revolt and climate protestors.
Could ClearVue tech have eased Spain’s pain?
ClearVue’s solar glass turns buildings into energy hubs, cutting costs, easing grid strain and paving the way for potentially greener cities.
Explorers Podcast: White Cliff Minerals
White Cliff Minerals MD Troy Whittaker joins Barry FitzGerald to dig into a big time red metal reveal in the Great White North.
More Stories
RML doubles down on gold/antimony drill targets
Resolution Minerals is planning mapping and sampling after interim LiDAR results reveal hundreds of historical workings at Drake East Antimony-Gold project.
AQX drills ups Viani gold prospectivity
Alice Queen’s drilling has demonstrated the continuity of high-grade epithermal gold at Dakuniba, boosting the prospectivity of the Viani project in Fiji.
Explorers Podcast: Trek Metals
In this Explorers Podcast instalment, Barry FitzGerald speaks to Trek Metals (ASX:TKM) CEO Derek Marshall to discuss the company’s recent ventures across its portfolio of exciting projects.
Explorers Podcast: Hillgrove Resources
Barry chats with Hillgrove Resources CEO and MD Bob Fulker about raising cash and the production profile of its Kanmantoo copper mine.
Gold price leads to M&A wave
With gold prices soaring we take a look at five logical M&A moves that could make sense as dealmaking heats up.
Errawarra acquires silver-rich ground
On the back of acquiring silver-rich tenements in WA’s Pilbara, Errawarra Resources is a major small cap mover, increasing 140% to 6.5c.
ASX closes day in positive territory
The ASX 200 pushed into the green on a choppy Monday as fears around Trump’s tariffs trade war were somewhat quelled.
Opthea fails major eye disease trial
One of two of Opthea’s phase III trials for a common eye disease has failed to meet its primary endpoints, thus casting doubts on the company’s solvency.
Original URL: https://www.couriermail.com.au/business/stockhead/page/180